{"anticipatedPostingDate":"2027-09","denomUnitsSelected":"Participants","description":"Participants with potentially clinically significant abnormalities in vital signs were summarized for the following parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Potentially clinically significant abnormalities were defined as (1) SBP (mmHg): \\>180 and increase from baseline \\>40; \\<90 and decrease from baseline \\>30; final visit or 2 consecutive visits change from baseline (CFB) ≥10, ≥15, ≥20; final visit or most extreme result ≥140, ≥180, ≥140 and ≥20 CFB, ≥180 and ≥20 CFB; (2) DBP (mmHg): \\>105 and increase from baseline \\>30; \\<50 and decrease from baseline \\>20; final visit or 2 consecutive visits CFB ≥5, ≥10, ≥15; final visit or most extreme result ≥90, ≥105, ≥90 and ≥15 CFB, ≥105 and ≥15 CFB; (3) HR (bpm): \\>120 and increase from baseline \\>30; \\<50 and decrease from baseline \\>20.","reportingStatus":"NOT_POSTED","timeFrame":"From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)","title":"Number of Participants With Potentially Clinically Significant Vital Signs - at PCD Cut-off Date of 31 January 2023","type":"SECONDARY"}